Key Points
- Insider transaction: Jason Kelly sold 963 Inspire Medical Systems shares at an average price of $59.55, receiving $57,346.65. His remaining stake fell 4.83% to 18,985 shares.
- Quarterly performance: Inspire reported earnings of $0.14 per share, beating consensus estimates by $0.38, while revenue of $200.58 million also exceeded expectations. However, revenue declined 7.6% year over year.
- Market outlook: Institutional investors own 94.91% of the stock, while analysts maintain an overall “Hold” rating with an average price target of $68.00. INSP recently traded near $59.25, within a 12-month range of $38.91 to $147.03.
Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) insider Jason Kelly sold 963 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares of the company's stock, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Inspire Medical Systems Price Performance
NYSE INSP opened at $59.25 on Wednesday. Inspire Medical Systems, Inc. has a 12 month low of $38.91 and a 12 month high of $147.03. The company has a market capitalization of $1.71 billion, a P/E ratio of 12.83, a PEG ratio of 4.54 and a beta of 0.70. The company's 50 day simple moving average is $48.39 and its 200 day simple moving average is $53.75.
Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.38. The firm had revenue of $200.58 million during the quarter, compared to analysts' expectations of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The firm's revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period last year, the firm posted $0.45 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, analysts anticipate that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current year.
Institutional Trading of Inspire Medical Systems
A number of hedge funds have recently made changes to their positions in INSP. CWM LLC grew its position in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. Havemeyer Place LP purchased a new stake in Inspire Medical Systems in the 4th quarter worth approximately $39,000. V Square Quantitative Management LLC acquired a new stake in shares of Inspire Medical Systems during the 4th quarter valued at $40,000. Smartleaf Asset Management LLC boosted its stake in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the period. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company's stock valued at $60,000 after buying an additional 130 shares during the period. 94.91% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on the company. Evercore set a $54.00 target price on Inspire Medical Systems in a report on Tuesday, August 4th. UBS Group started coverage on shares of Inspire Medical Systems in a report on Tuesday, July 28th. They set a "sell" rating and a $39.00 price target on the stock. KeyCorp restated a "sector weight" rating on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Piper Sandler raised their price objective on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 4th. Finally, Robert W. Baird lifted their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $68.00.
Read Our Latest Stock Analysis on INSP
Inspire Medical Systems Company Profile
(
Get Free Report)
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
